(Q31078568)

28 June 2017

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma (English)

1 reference

28 June 2017

1 reference

Jianxin Zhao

1

1 reference

28 June 2017

Rina Wu

2

1 reference

28 June 2017

Alfred Au

3

1 reference

28 June 2017

Abbey Marquez

4

1 reference

28 June 2017

Yibing Yu

5

1 reference

28 June 2017

Zuorong Shi

6

1 reference

28 June 2017

1 June 2002

1 reference

28 June 2017

1 reference

28 June 2017

15

1 reference

28 June 2017

657-665

1 reference

28 June 2017

6

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

28 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Studies of the HER-2/neu proto-oncogene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

C-erbB-2 immunostaining: problems with interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

The HercepTest assay: another perspective

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Testing for erbB-2 by immunohistochemistry in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Molecular cytogenetics of primary breast cancer by CGH

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

10.1038/MODPATHOL.3880582

Identifiers

DOI

1 reference

Dimensions Publication ID

28 June 2017

0 references

1 reference